25 September 2020 - - US-based COVID-19 testing startup Curative, Inc. has launched a new COVID-19 study in the city of San Antonio.

The research aims to better understand how video-assisted and observed self-collected oral swab samples and nasal swab samples compare to provider-collected nasal swab samples for the detection of COVID-19. Self-collected samples reduce reliance on the supply of personal protective equipment (masks, gloves and lab coats) and prevent potential exposure of our doctors or nurses to novel Coronavirus.

Curative is seeking participants for this study. To qualify for the study, participants must have no COVID-related symptoms that meet the CDC guidelines as evaluated by a healthcare practitioner.
Symptoms include shortness of breath, difficulty breathing, or cough.

Those that take part in the research may have to do a self-collected oral and nasal swab, blood sample, clinician collected nasal and nasopharyngeal swab.

Curative also recently opened a new CLIA-certified laboratory facility based in Pflugerville, Texas to increase both availability and processing capacity for the state by 10,000 tests per day, using the company's FDA authorised oral fluid COVID-19 test.

The test is painless and simple to use with turnaround times within 48 hours.

Since its founding in January, Curative has become one of the leading COVID-19 testing providers. The company has tested over 4m samples across the US and tests approximately 70,000 samples per day.

Curative also operates the country's largest COVID-19 testing site at Dodgers Stadium in Los Angeles.

Curative Inc. was founded to develop tests for sepsis in January 2020 and pivoted to COVID-19 in early March 2020 upon realizing the urgent need for test development and production in the United States. Curative is currently operational within a CLIA-certified lab in Los Angeles, CA and Washington, DC Founded by Fred Turner and comprised of a team of doctors, scientists, engineers, and health industry experts, Curative is rapidly scaling its simple-to-use oral fluid COVID-19 tests to reach the groups most in need of testing.